Oscar Health (NYSE:OSCR) Announces Quarterly Earnings Results

Oscar Health (NYSE:OSCR) posted its quarterly earnings data on Thursday. The company reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.63, FiscalAI reports. The company had revenue of $5.14 billion for the quarter, compared to analyst estimates of $4.69 billion. Oscar Health had a net margin of 4.90% and a return on equity of 54.57%. Oscar Health’s quarterly revenue was up 72.1% on a year-over-year basis. During the same period in the previous year, the business posted ($0.53) earnings per share.

Here are the key takeaways from Oscar Health’s conference call:

• Oscar raised its 2026 earnings-from-operations guidance for the third time, to $850 million–$950 million, citing favorable risk-adjustment results and utilization that was moderately better than expected. Through nine months, the company reported $1.2 billion in net income and $1.3 billion in earnings from operations.
• Third-quarter revenue rose 70% year over year to $5.1 billion, while the medical loss ratio improved to 84% and the SG&A expense ratio fell to a company-record 14%. Management attributed the efficiency gains to pricing discipline, fixed-cost leverage, expense controls, and technology and AI initiatives.
• Membership grew 27% year over year to 2.7 million, and Oscar is entering open enrollment across 713 counties, including a new South Carolina market. The company is also expanding products such as RetireEase and CHOICE, while its Lucie platform is projected to sell about 800,000 policies in 2027.
• For 2027, management expects overall ACA marketplace membership to be roughly stable year over year while aiming to gain share; its average rate increase is about 14%, reflecting high-single-digit medical-cost trend, higher market morbidity, and some margin expansion. New eligibility checks could create enrollment friction, though Oscar says it has prepared broker tools to help manage the process.
• Management cautioned that the $250 million third-quarter revenue benefit from updated risk-adjustment data does not all flow to earnings and is maintaining conservative reserves. Outpatient utilization was elevated, and Oscar expects a normal seasonal increase in fourth-quarter MLR.

Oscar Health Price Performance

Shares of NYSE OSCR traded down $2.44 during midday trading on Friday, hitting $30.74. The company had a trading volume of 8,874,950 shares, compared to its average volume of 5,394,969. The firm has a market capitalization of $9.49 billion, a price-to-earnings ratio of 12.67, a price-to-earnings-growth ratio of 0.34 and a beta of 2.56. Oscar Health has a twelve month low of $10.69 and a twelve month high of $38.50. The business has a 50-day simple moving average of $31.81 and a two-hundred day simple moving average of $23.97. The company has a quick ratio of 1.09, a current ratio of 1.09 and a debt-to-equity ratio of 0.21.

Trending Headlines about Oscar Health

Here are the key news stories impacting Oscar Health this week:

• Positive Sentiment: Oscar reported Q3 adjusted earnings of $0.49 per share, versus analysts’ expected loss, and revenue of $5.14 billion, topping the $4.69 billion estimate and rising 72.1% year over year. Oscar Health beats Q3 earnings and revenue estimates
• Positive Sentiment: The company raised its 2026 revenue outlook to $19 billion–$19.3 billion, above the $18.64 billion FactSet estimate, and increased its full-year earnings outlook. Management cited improving medical costs and operating efficiencies as supporting margin gains, with expansion expected to contribute to 2027 growth. Q3 earnings call highlights outlook and margin gains
• Positive Sentiment: Operational indicators were also encouraging: membership increased 27.2% to 2.69 million, the medical loss ratio improved to 84.0%, and Oscar swung to a $167.3 million profit. Oscar Health Q3 revenue and membership growth
• Positive Sentiment: Zacks added OSCR to its Rank #1 (Strong Buy) growth-stocks list, reflecting favorable quantitative signals. Zacks growth stocks list
• Negative Sentiment: Piper Sandler lowered its price target from $48 to $45, although it maintained an Overweight rating. The new target still implies substantial upside from the referenced $30.74 share price. Piper Sandler rating information

Analysts Set New Price Targets

Several brokerages have recently weighed in on OSCR. UBS Group lifted their target price on shares of Oscar Health from $26.00 to $36.00 and gave the company a “neutral” rating in a report on Monday, October 12th. Weiss Ratings raised shares of Oscar Health from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, October 8th. Stephens restated an “equal weight” rating and issued a $34.00 price objective on shares of Oscar Health in a research report on Thursday, September 17th. Barclays lifted their price objective on Oscar Health from $39.00 to $49.00 and gave the company an “overweight” rating in a report on Thursday, September 17th. Finally, Raymond James Financial lifted their price objective on Oscar Health from $34.00 to $42.00 and gave the company an “outperform” rating in a report on Friday, September 18th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Oscar Health has an average rating of “Hold” and an average price target of $34.60.

Insider Activity at Oscar Health

In other news, insider Adam Mcananey sold 9,092 shares of Oscar Health stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $31.45, for a total transaction of $285,943.40. Following the completion of the sale, the insider directly owned 209,004 shares in the company, valued at approximately $6,573,175.80. This trade represents a 4.17% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Janet Liang sold 10,360 shares of Oscar Health stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $31.45, for a total transaction of $325,822.00. Following the sale, the insider owned 248,697 shares of the company’s stock, valued at approximately $7,821,520.65. The trade was a 4.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 874,451 shares of company stock valued at $26,761,671 in the last ninety days. Company insiders own 22.64% of the company’s stock.

Oscar Health Company Profile

Oscar Health, Inc is a technology-focused health insurance company that provides health plans and related services in the United States. The company primarily serves individuals and families purchasing coverage through the Affordable Care Act’s health insurance marketplace, as well as small businesses and their employees.

Oscar combines health insurance products with digital tools designed to help members manage their care. Its services include online enrollment, virtual care, provider search and appointment support, care navigation, claims and benefits information, and member engagement through web and mobile applications.